A detailed history of Jpmorgan Chase & CO transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,787 shares of IGMS stock, worth $44,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,787
Previous 7,073 4.04%
Holding current value
$44,183
Previous $48,000 133.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$6.28 - $17.68 $1,796 - $5,056
-286 Reduced 4.04%
6,787 $112,000
Q2 2024

Aug 12, 2024

BUY
$6.51 - $11.47 $8,052 - $14,188
1,237 Added 21.2%
7,073 $48,000
Q1 2024

May 10, 2024

SELL
$8.68 - $17.36 $33,921 - $67,842
-3,908 Reduced 40.11%
5,836 $56,000
Q4 2023

Feb 12, 2024

SELL
$3.94 - $8.79 $17,852 - $39,827
-4,531 Reduced 31.74%
9,744 $80,000
Q3 2023

Nov 14, 2023

BUY
$6.66 - $10.64 $22,184 - $35,441
3,331 Added 30.44%
14,275 $119,000
Q2 2023

Aug 11, 2023

SELL
$8.86 - $14.0 $25,304 - $39,984
-2,856 Reduced 20.7%
10,944 $101,000
Q1 2023

May 18, 2023

BUY
$13.74 - $25.76 $169,592 - $317,955
12,343 Added 847.15%
13,800 $189,000
Q1 2023

May 11, 2023

SELL
$13.74 - $25.76 $134,074 - $251,366
-9,758 Reduced 87.01%
1,457 $20,000
Q4 2022

Feb 13, 2023

BUY
$15.45 - $26.02 $3,445 - $5,802
223 Added 2.03%
11,215 $191,000
Q3 2022

Nov 14, 2022

BUY
$15.42 - $27.01 $15,898 - $27,847
1,031 Added 10.35%
10,992 $250,000
Q2 2022

Aug 11, 2022

SELL
$13.27 - $25.5 $22,174 - $42,610
-1,671 Reduced 14.37%
9,961 $180,000
Q1 2022

May 11, 2022

BUY
$13.42 - $29.73 $55,223 - $122,338
4,115 Added 54.74%
11,632 $312,000
Q4 2021

Feb 10, 2022

BUY
$27.59 - $66.39 $23,782 - $57,228
862 Added 12.95%
7,517 $220,000
Q3 2021

Nov 12, 2021

BUY
$65.76 - $90.65 $437,632 - $603,275
6,655 New
6,655 $437,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $189M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.